OKYO Pharma (STU:OK10) EPS (Basic): €-0.10 (TTM As of Sep. 2025)

What is OKYO Pharma EPS (Basic)?

OKYO Pharma STU:OK10 23 EPS (Basic) is €-0.10 as of Sep. 2025. GuruFocus rates STU:OK10 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

OKYO Pharma's basic earnings per share (Basic EPS) for the six months ended in Sep. 2025 was €-0.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2025 was €-0.10.

OKYO Pharma's EPS (Diluted) for the six months ended in Sep. 2025 was €-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was €-0.10.

OKYO Pharma's EPS without NRI for the six months ended in Sep. 2025 was €-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was -0.10.

During the past 3 years, the average EPS without NRI Growth Rate was 30.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -91.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, OKYO Pharma's highest 3-Year average EPS without NRI Growth Rate was 60.30% per year. The lowest was -573.10% per year. And the median was -21.30% per year.

OKYO Pharma (STU:OK10) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

OKYO Pharma EPS (Basic) Related Terms

OKYO Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma EPS (Basic) Chart

OKYO Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

EPS (Basic)

Get a 7-Day Free Trial

-0.27

-0.33

-0.57

-0.52

-0.11

OKYO Pharma Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25
EPS (Basic)	Get a 7-Day Free Trial															-0.25	-0.28	-0.07	-0.04	-0.06

23GF Score

OKYO Pharma Ltd STU:OK10

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

OKYO Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

OKYO Pharma's Basic EPS for the fiscal year that ended in Mar. 2025 is calculated as

Basic EPS (A: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.353	-	0)	/	39.488
	=	-0.11

OKYO Pharma's Basic EPS for the quarter that ended in Sep. 2025 is calculated as

Basic EPS (Q: Sep. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.204	-	0)	/	37.421
	=	-0.06

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.10

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of €-0.10 mean?

OKYO Pharma (STU:OK10) has a EPS (Basic) of €-0.10 as of Sep. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on OKYO Pharma and its competitors.

Is OKYO Pharma's EPS (Basic) too high?

OKYO Pharma's current EPS (Basic) is €-0.10. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.

How does OKYO Pharma's EPS (Basic) compare to SGMO and AARD?

OKYO Pharma's EPS (Basic) of €-0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current EPS (Basic) is €-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is OKYO Pharma stock overvalued right now?

OKYO Pharma (STU:OK10) has a current EPS (Basic) of €-0.10. The current EPS (Basic) is €-0.10. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For OKYO Pharma (STU:OK10), the current EPS (Basic) is €-0.10 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies SGMO AARD ANIX TELO PYPD LONA CUE ICCC NRXS PTHS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges OKYO:USA

Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ

Website https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

23GF Score

Get the complete analysis for STU:OK10

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.16

Price

View STU:OK10 Analysis

See EPS (Basic) data for all stocks →